The levonorgestrel-releasing intrauterine device reduces CA-125 serum levels in patients with endometriosis
RCT
OA: bronze
CC0
⤵ 32 in-corpus citations
AI-generated summary
This study investigated the effect of the levonorgestrel-releasing intrauterine device on CA-125 serum levels in patients with endometriosis and found a reduction.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
This study compared the long-term effects of the levonorgestrel-releasing intrauterine device with those of GnRH agonist administration on serum levels of CA-125 in patients with endometriosis. The levonorgestrel-releasing intrauterine device was found to be as efficient as GnRH agonist in reducing CA-125 serum levels.
My notes (saved in your browser only)
Condition tags
MeSH descriptors
Citation neighborhood (2-hop)
Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. Outer rings show 2-hop neighbours — papers reached through the immediate citers/citees. [ collapse to 1-hop ]
References (20)
- A levonorgestrel-releasing intrauterine system for the treatment of dysmenorrhea associated with endometriosis: a pilot study via openalex
- [Clinical significance of CA19-9 for endometriosis] via openalex
- Comparison of the effects of leuprorelin acetate and danazol treatments on serum CA-125 levels in women with endometriosis via openalex
- Effect of GnRH analogues on apoptosis and release of interleukin-1beta and vascular endothelial growth factor in endometrial cell cultures from patients with endometriosis via openalex
- Fluctuations in CA 125 and CA 15-3 serum concentrations during spontaneous ovulatory cycles via openalex
- High concentrations of the CA-125, CA 19-9 and CA 15-3 in the peritoneal fluid between patients with and without endometriosis via openalex
- Immunohistochemical analysis of CA125, CA19-9, and Ki-67 in stage III or IV endometriosis: positive correlation between serum CA125 level and endometriotic epithelial cell proliferation via openalex
- Serum CA-125 in preoperative patients at high risk for endometriosis via openalex
- Serum CA 125 levels in patients with endometriosis: changes in CA 125 levels during menstruation via openalex
- The evaluation of the effectiveness of an intrauterine-administered progestogen (levonorgestrel) in the symptomatic treatment of endometriosis and in the staging of the disease via openalex
- Usefulness and limits of CA-125 in diagnosis of endometriosis without associated ovarian endometriomas via openalex
- W2087512818 via openalex
- W2200427146 via openalex
- W1978677754 via openalex
- W6603012515 via openalex
- W6607846724 via openalex
- W6656330334 via openalex
- W6668890459 via openalex
- W2123134517 via openalex
- W6687377576 via openalex
Cited by (31)
- Gonadotropin-releasing hormone analogues for endometriosis 2023
- AVALIAÇÃO DE BIOMARCADORES EM MULHERES COM ENDOMETRIOSE E DOR USUÁRIAS DO IMPLANTE COM ETONOGESTREL OU SISTEMA INTRAUTERINO COM LEVONORGESTREL: ENSAIO CLÍNICO RANDOMIZADO 2022
- Avaliação de dois biomarcadores e de escores de dor pélvica crônica associada à endometriose em usuárias do implante com etonogestrel e do sistema intrauterino com levonorgestrel de 52 mg por 24 meses; e avaliação das vivências dos parceiros destas mulheres após o tratamento 2022
- Non-contraceptive Benefits of Hormonal Methods 2021
- Levonorgestrel-releasing intrauterine device (LNG-IUD) for symptomatic endometriosis following surgery 2021
- Assessment of biomarkers in women with endometriosis-associated pain using the ENG contraceptive implant or the 52 mg LNG-IUS: a non-inferiority randomised clinical trial 2018
- Tratamientos farmacológicos de la endometriosis (a excepción de la adenomiosis) 2018
- Avaliação de biomarcadores em mulheres com endometriose e dor usuárias do implante liberador de etonogestrel ou sistema intrauterino liberador de levonorgestrel = Assessment of biomarkers among women with endometriosis-associated pain users of the etonogestrel-releasing contraceptive implant or 52-mg levonorgestrel releasing intrauterine system: randomized clinical trial 2018
- Reviewing the role of progesterone therapy in endometriosis 2018
- The Use of Resveratrol as an Adjuvant Treatment of Pain in Endometriosis: A Randomized Clinical Trial 2017
- Harmonization of Clinical and Laboratory Data to Improve Biomarker Discovery in Endometriosis: WERF EPHect 2017
- Evaluation of oxidative stress markers and intra-extracellular antioxidant activities in patients with endometriosis 2016
- Hormonal therapy for endometriosis: from molecular research to bedside 2016
- Hormonal treatment for severe hydronephrosis caused by bladder endometriosis 2014
- World Endometriosis Research Foundation Endometriosis Phenome and Biobanking Harmonization Project: II. Clinical and covariate phenotype data collection in endometriosis research 2014
- Analysis of the levonorgestrel-releasing intrauterine system in women with endometriosis 2013
- Levonorgestrel-releasing intrauterine device (LNG-IUD) for symptomatic endometriosis following surgery 2013
- Serum HE4 concentration is not dependent on menstrual cycle or hormonal treatment among endometriosis patients and healthy premenopausal women 2012
- Emerging indications for the levonorgestrel-releasing intrauterine system (LNG-IUS) 2011
- Surgical Therapies: Pouch of Douglas and Uterovaginal Pouch Resection for Endometriosis 2011
- Vaginal danazol for women with rectovaginal endometriosis and pain symptoms persisting after insertion of a levonorgestrel-releasing intrauterine device 2011
- Role of eutopic endometrium in pelvic endometriosis 2011
- Gonadotrophin-releasing hormone analogues for pain associated with endometriosis 2010
- Efeitos do sistema intra-uterino de Levonorgestrel sobre marcadores de risco cardiovascular de pacientes com endometriose: estudo comparativo com o análogo do GnRH 2009
- Levonorgestrelį išskiriančios gimdos spiralės vartojimas ginekologijoje 2009
- Effects of the levonorgestrel-releasing intrauterine system on cell proliferation, Fas expression and steroid receptors in endometriosis lesions and normal endometrium 2009
- Targeting mast cells in endometriosis with janus kinase 3 inhibitor, JANEX-1 2007
- Avaliação das dosagens das interleucinas 12 e 18 no sangue e no fluido peritoneal de pacientes com endometriose pélvica 2007
- The levonorgestrel-releasing intrauterine system and endometriosis staging 2007
- Expressão gênica diferencial em tecido endometrial tópico e lesões endometrióticas 2007
- Tratamento da endometriose 2006
Source provenance
- europepmc
- last seen: 2026-10-19T06:17:24.038039+00:00
- openalex
- last seen: 2026-06-10T17:14:06.276822+00:00
- pubmed
- last seen: 2026-10-08T21:03:51.313027+00:00
License: CC0
· commercial use OK